Provider Statement

HMP Education

Provided by HMP Education, an HMP Global Company.

Intended Learners

This educational activity is designed for advanced practice registered nurses, nurse practitioners and other nursing professionals, physicians, podiatrists, pharmacists, physician assistants, and dietitians. 

Learning Objectives

After participating in this activity, learners should be better able to:

  • Examine how different pharmacologic agents affect wounds and their healing processes

  • Summarize adjunctive therapies that may be used in conjunction with medication therapy for acute and chronic wounds

  • Identify methods for managing soft tissue and bone infections, bioburden, and local and systemic infections

  • Employ an appropriate therapeutic regimen that maximizes therapeutic effectiveness while minimizing adverse reactions

Activity Overview

To be eligible for documentation of credit, participants must attend the full activity and submit a completed evaluation form. Participants who complete the evaluation online within 1 year of the training will be able to receive immediate documentation of credit. For questions regarding this educational activity, please email

Release Date: February 29, 2024
Expiration Date: February 28, 2025
Estimated Time to Complete: 39.75 hours 

Hardware/Software Requirements

The activity is best supported via a computer or device with a current version of one of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print content.

Continuing Education 


In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.


HMP Education designates this enduring activity for 39.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This enduring, knowledge-based activity (Universal Activity Number JA0006201-0000-24-033-H01-P) has been approved for 39.75 contact hours (3.975 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


This continuing nursing education enduring activity awards 39.75 contact hours. 

Nurse Practitioners

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Physician Assistants/Associates 

AAPAHMP Education has been authorized by the American Academy of Physician Assistants (AAPA) to award  AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This enduring activity is designated for 39.75 AAPA Category 1 credits. Approval is valid until February 28, 2025. PAs should claim only the credit commensurate with the extent of their participation.



Use of Proprietary Names 

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

Unapproved and/or Investigations Uses of Drugs and Devices

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters, or moderators and do not necessarily reflect the opinions of HMP Education.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own healthcare provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Disclosure of Relevant Financial Relationships

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to and mitigating all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company; and
  2. Any investigational, off-label, or non–FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure:

  1. All recommendations involving clinical medicine are based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and nonpromotional.

All relevant financial relationships have been mitigated.


The faculty have reported the following:

Maria Abreu: Consultant, Advisory Board – AbbVie, Amgen, Bristol Myers Squibb, Celsius Therapeutics, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals, Microba Life Sciences, Pfizer, Prometheus Biosciences, UCB Biopharma SRL; Research Funding – National Institute of Health Research, DOD, Leona M. and Harry B. Helmsley Charitable Trust​

Afsaneh Alavi: Consultant – AbbVie, Janssen, Novartis, InflaRx, BI, UCB

Oscar Alvarez: Advisory Board – Cell Constructs LLC, Molnlycke; Consultant – BioCompression Inc Scientific; Grant/Research Suppor – Molnlycke Health Care Sanuwave, Inc

Andrew Boulton: Consultant – Bayer Pharmaceuticals Inc, German, AstraZeneca

Abigail Chaffin: Consultant – AROA Biosurgery, URGO Medical North America

Amanda Killeen: Grant/Research Support – 3M/KCI, Acera Surgical, American Diabetes Association, AstraZeneca, BioTissue Surgical, Hologenix LLC, Integra LifeSciences, Kent Imaging, Microbion Biosciences, Polarity TE, Smith + Nephew, Stark Enterprises LLC, VasoActiv, ViOptix, Xyken

Robert Kirsner: Consultant – Pfizer Inc, Smith & Nephew

Kathryn Kreider: Advisory Board – Novo Nordisk; Speakers Bureau – Novo Nordisk

Warren Joseph: Speakers Bureau – Paratek Pharma

Hadar Lev-Tov: AbbVie – Advisory Board; Consultant – Molnycke, NextScience, Pfizer, Inc.; Grant/Research Support – Essity, Molnycke, NextScience, Vomaris Inc

Edward Loftus: Consultant – AbbVie, Alvotech, Amgen, Astellas, Avalo, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Health, Janssen, Morphic, Ono, Protagonist, Sun, Surrozen, Takeda, TR1X, UCB; Research Support – Janssen, Takeda, AbbVie, UCB, Genentech, Gilead, Celgene/Receptos, Bristol Myers Squibb, Theravance, Gossamer Bio​

Millie Long: Consultant – AbbVie, Takeda, Janssen, Pfizer, Lilly, BMS, Prometheus, Target RWE, Intercept, Roivant; Research Support – Takeda, Pfizer, Lilly​

Brian Machler: Speakers Bureau – Sanofi Regeneron

Paul Michael: Consultant – Philips, Abbott, Boston Scientific; Speakers Bureau – Medtronic

Caterina Minniti: Advisory Board – Global Blood Therapeutics; Consultant – Agios, Bluebird Bio, Chiesi, CSL Behring, Forma Therapeutics, Global Blood Therapeutics, Novartis, Roche; Speakers Bureau – Novartis

Elliot Mostow: Other Financial or Material Support – Associate Editor, Dermatology Channel,, Elsevier

Christine Murphy: Advisory Board – 3M/KCI, URGO, Convatec; Consultant – 3M/KCI, Convatec

Mary Anne Obst: Co-patent owner – Fistula Solution; Speakers Bureau – KCI

Alex Ortega: Advisory Board – Boehringer Ingelheim, Bristol Myers Squibb, Janssen Biotech; Consultant – Corvus Pharma, Genetech, Guidepoint Global; Grant/Research Support – AbbVie Inc, Eli Lilly Pharmaceuticals, Janssen Biotech, Pfizer Inc

George Pliagas: Consultant – CARDIOVASCULAR SYSTEMS INC; Speakers Bureau – Asahi, CARDIOVASCULAR SYSTEMS INC, Medtronic, Philips; Stockholder – Penumbra

David Rubin: Consultant/Advisor – AbbVie, Altrubio, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chronicles, Syneos, ClostraBio, Connect BioPharma, Eco R1, Genentech/Roche, Gilead Sciences, Iterative Health, Image Analysis Group, Janssen Pharmaceuticals, Kaleido Biosciences, Lilly, Pfizer, Prometheus Biosciences, Reistone, Seres Therapeutics, Takeda, Target RWE, Trellus Health; Grant Support – Takeda, Helmsley Charitable Trust, GastroIntestinal Research Foundation; Board of Trustees – Crohn’s & Colitis Foundation, Cornerstones Health Inc​

Bruce Sands: Consultant or received speaker’s fees – AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Enthera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead Sciences, Genentech, GlaxoSmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio; Stock Options – Ventyx Biosciences

Heather Woolery-Lloyd: Grant/Research Support – Allergan, Galderma, Pfizer; Speakers Bureau – EPI Health, Ortho Dermatologics; Major Stockholder – Somabella Laboratories, LLC


Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California

Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

HMP Education planners and staff include Kristin Ciszeski; Krystal Scharon; Samantha Joy; Randy Robbin; and Andrea Zimmerman, EdD.

No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

ADA Statement

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity needs accommodations, please call 609.371.1137.

Privacy Policy

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. HMP Education and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information. Copyright © 2024 by HMP Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.

Commercial Support

No commercial interest provided financial support for this continuing education activity. 

Contact Information

If you have any questions/comments, please contact us here with "HMP Education | Pharmacology in Wound Care" as the subject line.